These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23829943)

  • 1. A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors.
    Liu L; Zhang W; Li W; Lv F; Xia Z; Zhang S; Liu W; Zandvliet AS; Waajen S; Zhang LX; Yan L; Li J
    J Hematol Oncol; 2013 Jul; 6():48. PubMed ID: 23829943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors.
    Seki Y; Yamamoto N; Tamura Y; Goto Y; Shibata T; Tanioka M; Asahina H; Nokihara H; Yamada Y; Shimamoto T; Noguchi K; Tamura T
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1099-105. PubMed ID: 22143378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
    Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
    BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.
    Pearson AD; Federico SM; Aerts I; Hargrave DR; DuBois SG; Iannone R; Geschwindt RD; Wang R; Haluska FG; Trippett TM; Geoerger B
    Oncotarget; 2016 Dec; 7(51):84736-84747. PubMed ID: 27713169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.
    Mita MM; Poplin E; Britten CD; Tap WD; Rubin EH; Scott BB; Berk L; Rivera VM; Loewy JW; Dodion P; Haluska F; Sarantopoulos J; Mita A; Tolcher A
    Ann Oncol; 2013 Apr; 24(4):1104-11. PubMed ID: 23211938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.
    Gore L; Trippett TM; Katzenstein HM; Boklan J; Narendran A; Smith A; Macy ME; Rolla K; ; Narashimhan N; Squillace RM; Turner CD; Haluska FG; Nieder M
    Clin Cancer Res; 2013 Jul; 19(13):3649-58. PubMed ID: 23659969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.
    Piha-Paul SA; Munster PN; Hollebecque A; Argilés G; Dajani O; Cheng JD; Wang R; Swift A; Tosolini A; Gupta S
    Eur J Cancer; 2015 Sep; 51(14):1865-73. PubMed ID: 26199039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.
    Sessa C; Tosi D; Viganò L; Albanell J; Hess D; Maur M; Cresta S; Locatelli A; Angst R; Rojo F; Coceani N; Rivera VM; Berk L; Haluska F; Gianni L
    Ann Oncol; 2010 Jun; 21(6):1315-1322. PubMed ID: 19901013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial.
    Reardon DA; Wen PY; Alfred Yung WK; Berk L; Narasimhan N; Turner CD; Clackson T; Rivera VM; Vogelbaum MA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):849-60. PubMed ID: 22037923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
    Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
    J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
    Chawla SP; Staddon AP; Baker LH; Schuetze SM; Tolcher AW; D'Amato GZ; Blay JY; Mita MM; Sankhala KK; Berk L; Rivera VM; Clackson T; Loewy JW; Haluska FG; Demetri GD
    J Clin Oncol; 2012 Jan; 30(1):78-84. PubMed ID: 22067397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
    Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
    J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers.
    Nemunaitis J; Hochster HS; Lustgarten S; Rhodes R; Ebbinghaus S; Turner CD; Dodion PF; Mita MM
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):336-42. PubMed ID: 23615181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
    Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
    J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.
    Frappaz D; Federico SM; Pearson AD; Gore L; Macy ME; DuBois SG; Aerts I; Iannone R; Geschwindt R; Van Schanke A; Wang R; Geoerger B
    Eur J Cancer; 2016 Jul; 62():9-17. PubMed ID: 27185573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
    Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
    Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.
    Colombo N; McMeekin DS; Schwartz PE; Sessa C; Gehrig PA; Holloway R; Braly P; Matei D; Morosky A; Dodion PF; Einstein MH; Haluska F
    Br J Cancer; 2013 Mar; 108(5):1021-6. PubMed ID: 23403817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The minimal impact of food on the pharmacokinetics of ridaforolimus.
    Stroh M; Li X; Marsilio S; Panebianco D; Johnson-Levonas A; Juan A; Orford K; Agrawal N; Trucksis M; Wagner JA; Murphy G; Iwamoto M
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):177-82. PubMed ID: 22669570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.
    Lush RM; Patnaik A; Sullivan D; Papadopoulos KP; Trucksis M; McCrea J; Cerchio K; Li X; Stroh M; Selverian D; Orford K; Ebbinghaus S; Agrawal N; Iwamoto M; Wagner JA; Tolcher A
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):567-74. PubMed ID: 22878520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
    Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.